ConsulTech Logo

SME instrument gets EIC accelerator

The EC updates the "SME instrument". The new funding instrument "EIC Accelerator Pilot" (formerly: SME Instrument Phase 2) will be installed in preparation for the forthcoming EU Framework Programme "Horizon Europe (2021-2027)". Read More…

ConsulTech at the Bionnale

ConsulTech will attend the Bionnale, the biggest networking event for life sciences and healthcare industries in the Berlin/Brandenburg area. Representatives from academia and industry attend to identify, engage and start strategic relationships. At our booth we will present e-Col, our IT solution to facilitate collaboration and management of project consortia, and the BMBF funded project VSOP that we support as project coordinator. Read More…

ConsulTech at the German Biotech Days

The German Biotech Days are one of the largest events of the biotech scene in the German speaking regions. ConsulTech will have a booth and present e-Col, our IT solution to facilitate collaboration and management of project consortia. Of course, we are open to discuss funding opportunities for your project. Read More…

IMI2- Call 17 published

The Innovative Medicines Initiative 2 (IMI2) hast published the 17th call. It addresses the following topics: Read More…

e-Col - Online Collaboration and Authoring Platform

e-Col is an IT-system that allows to work on the same Microsoft® document (Word, Excel, PowerPoint) with many team members at the same time. c-Col is a GDPR compliant cloud-based solution offering completely private e-rooms.
In addition, it provides many features enabling true collaborative work such as limitless file sharing, to-do lists and calendar, chat, VoIP and video calls.
Read More…

EU: Innovative Medicines Initiative 2 (IMI2) - 15. Call

This call is open to submit project applications in following topics:

• Integrated research platforms enabling patient-centric drug development
• Blockchain enabled healthcare
• Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
• Emerging translational safety technologies and tools for interrogating human immuno-biology
• Development and validation of translational platforms in support of synaptopathy drug discovery
• Digital endpoints in neurodegenerative and immune-mediated diseases
• AMR Accelerator Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• AMR Accelerator Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
Read More…

GLIOMARK1 clinical study successfully completed

The GLIOMARK consortium is delighted to announce that the Gliomark1 Phase II clinical study has been successfully completed. Read More…

ConsulTech at BIO-Europe

ConsulTech participates at the BIO-Europe, which takes place in Berlin between 6th - 8th November 2017!
BIO-Europe is Europe’s biggest pharma and biotechnology partnering conference, bringing together decision makers from life science and the investors. The accompanying exhibition is an unmissable opportunity to meet new customers, and to present innovative ideas and projects to VC, customers and partners.
Meet the team using the partnering tool of the conference and discuss funding opportunities!
Read More…

Funding competition Biomedical catalyst 2017 - "feasibility studies and early-stage project"

Innovate UK and the Medical Research Council (MRC) are to invest up to £12 million in new and novel healthcare solutions. There are 2 competitions for UK micro, small and medium-sized enterprises (SMEs) in the latest round of the Biomedical Catalyst. These are for feasibility and early stage projects. Read More…

Horizon 2020 - European-Russian Initiative "ERA-Net RUS plus Call 2017"

The goal of the call will be to create a long-term research collaboration in the field of innovation between EU Member States/Associated Countries and Russia. Innovative research collaboration of a high standard between teams from EU Member States and/or Associated Countries and Russia will be supported through an open competition. Read More…